1. Compositions for solubilization, characterized in that in their formulations comprise a compound sparingly soluble in water (hereinafter - IFA) and acyclic polyisoprenoid (hereinafter - polyols) having the general empirical formula H- {CH-C (CH) = CH-CH} - [{CH-C (CH) = CH-CH}] - X and the general structural formula where each isoprene unit contains 5 carbon atoms, W - terminal isoprene unit, T - trans-isoprene unit, C - cis-isoprene unit , S - 2,3-digidroizoprenovoe link, and = 0-10, b = 0-39, c = 0-1, n = a + b + c = 4-40, wherein the ratio of polyalcohols: IFA has any arbitrary value in the range of 50: 1 (fifty to one) to 1:50 (one to fifty) .2. Compositions according to claim 1, characterized in that the polyalcohols are chosen polyprenols, then X - a group of formula ON.3. Compositions according to claim 1, characterized in that the polyalcohols are chosen polyprenyl, then X - a group of formula ORO3MM wherein M and M are the same or different and represent a hydrogen cation or a monovalent inorganic or organic cation, or M and M together are a divalent inorganic kationom.4. Compositions according to claim 1, characterized in that the polyalcohol is selected polyprenols and polyprenyl mixture in any arbitrary ratio therebetween in the range from 1: 100 to 100: 1.5. Compositions according to claim 1, characterized in that the MPC is selected imatinib (imatinib) CHNO.6 formula. Compositions according to claim 1, characterized in that the MPC is selected sorafenib (sorafenib) CHClFNO.7 formula. Compositions according to claim 1, characterized in that the MPC is selected gefitinib (gefitinib) CHClFNO.8 formula. Compositions according to claim 1, characterized in that the MPC is selected lapatinib (lapatinib) CHClFNOS.9 formula. Compositions according to claim 1, characterized in that the qual1. Композиции для солюбилизации, отличающиеся тем, что в своих составах содержат малорастворимые в воде соединения (далее - МРС) и ациклические полиизопреноиды (далее - по
